The Global Anti-Obesity Drug Market is estimated to be valued
at USD 25.87 Bn in 2025 and is expected to reach USD 82.55
Bn by 2032, exhibiting a compound annual growth rate (CAGR)
of 18.01% from 2025 to 2032. This strong market growth is
driven by the rising global prevalence of obesity and the increasing demand for
effective pharmaceutical treatments. Additionally, advancements in drug
formulations and the expansion of healthcare infrastructure across emerging
economies are expected to further accelerate market growth during the forecast
period.
Request Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/2824
Global Anti-Obesity Drug Market Key
Takeaways
According to Coherent Market Insights
(CMI), the global anti-obesity drug market size is expected to grow nearly 3.2X
by 2032, increasing from USD 25.87 Bn in 2025 to USD 82.55 Bn by 2032.
Global anti-obesity drug demand is
projected to rise at a CAGR of 18% from 2025 to 2032.
Prescription drugs segment is slated
to dominate the industry, accounting for nearly two-thirds of the global
anti-obesity drug market share by 2025.
Based on drug class, GLP-1 receptor
agonists segment is expected to account for a market share of 22.1% in 2025.
By route of administration, oral
segment is set to hold 32.1% of the anti-obesity drug industry share by 2025.
North America is expected to retain
its dominance, capturing 38.3% of the global market share in 2025.
Asia Pacific, with an estimated share
of 24.2% in 2025, is anticipated to emerge as a highly lucrative market for
anti-obesity drug companies during the assessment period.
Rising Obesity Burden Fueling Anti-Obesity
Drug Market Growth
Coherent Market Insights’ latest anti-obesity
drug market analysis outlines major factors driving growth. Increasing
prevalence of obesity and related chronic conditions like diabetes and cardiovascular
diseases is one such prominent growth driver.
Obesity is becoming a major global
health problem, with the number of affected people increasing rapidly.
According to the World Obesity Federation, more than 1 billion people will be
living with obesity by 2030. This surge is expected to drive demand for
anti-obesity drugs during the forecast period.
Also Read: Weight Loss and Obesity
Management Market Size, Share, & Trend Analysis Report for 2025-2032
High Treatment Costs and Non-Pharmacological
Approaches Limiting Growth
The global anti-obesity drug market
outlook remains positive, owing to rising incidence of obesity and other
lifestyle diseases. However, high cost of treatment and growing competition
from non-pharmacological approaches might slow down market growth to some
extent during the forecast period.
Prescription anti-obesity drugs and
newer therapies like GLP-1 receptor agonists are quite expensive. This makes
them inaccessible for a large portion of the population, thereby dampening
overall anti-obesity drug market demand.
In addition, many obese individuals
opt for dietary interventions and bariatric surgery. Likewise, popularity of
natural and alternative weight loss supplements is increasing. These, in turn,
could slow down growth of anti-obesity drug market during the forthcoming
period.
Immediate Delivery Available | Buy This Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2824
Rising Health and Wellness Awareness
Unlocking Growth Opportunities
People are
becoming more aware of the importance of maintaining a healthy lifestyle. This rising
focus on health and wellness is increasing interest in anti-obesity drugs that
support weight management. As a result, pharmaceutical companies are finding
new opportunities to expand in this market.
Rise of digital
health and online weight loss programs is also contributing to market growth.
Many of these programs recommend or include prescription anti-obesity drugs as
part of personalized treatment plans. This will also create a conducive
environment for the growth of anti-obesity market.
Emerging Anti-Obesity Drug Market
Trends
GLP-1 receptor
agonists like Eli Lilly’s Mounjaro and Novo Nordisk’s Wegovy are
revolutionizing obesity treatment. These anti-obesity drugs have significantly
reduced body weight in clinical trials. Their success in clinical trials is
driving higher demand, which is expected to boost growth in the global
anti-obesity drug market.
An emerging
trend in the anti-obesity drug market is the expansion into highly lucrative pockets.
Leading pharmaceutical companies are continuously introducing novel obesity
treatments across Asia Pacific nations. For instance, in June 2025, Novo
Nordisk launched its weight-loss drug Wegovy in India. This expansion is
expected to play a key role in boosting the global anti-obesity drug market
value during the forthcoming period.
There is
increasing research and interest in combination therapies, such as pairing
GLP-1 receptor agonists with other metabolic agents, to enhance efficacy as
well as support patient adherence. This growing trend is expected to support
market expansion in the coming years.
Top players
are focusing on developing newer, more effective agents, especially GLP-1
receptor agonists like semaglutide and dual agonists (GLP-1/GIP) with high
efficacy and fewer side effects. For instance, Novo Nordisk plans to initiate
late-stage clinical trials of its experimental obesity drug, amycretin, in both
injectable and oral forms during the first quarter of 2026. These advancements
will likely boost growth of the anti-obesity market.
Also Read: Weight Loss Supplements
Market Analysis & Forecast for 2025-2032
Analyst’s View
“The global anti-obesity drug industry is set to
experience strong growth, owing to rising prevalence of obesity, escalating
health and wellness awareness, growing popularity of combination therapies, and
advancements in new drug formulations,” said a senior CMI analyst.
Current Events and Their Impact on the Anti-Obesity
Drug Market
Event
Description
and Impact
GLP-1 Receptor Agonist Market Expansion and Innovation
Description: Next-generation
GLP-1 dual and triple agonists are being developed.
o Impact: Pipeline drugs like tirzepatide and
retatrutide are improving treatment effectiveness and expanding market
opportunities.
Asia-Pacific Market Penetration and Demographic Trends
Description: India is
experiencing a growing middle-class obesity epidemic.
Impact: Rising
disposable income and lifestyle-related diseases are creating a large
untapped market.
Technological Integration
Description: AI-powered personalized dosing
platforms are being explored.
Impact: Machine learning helps optimize treatment
outcomes and reduce side effects, which encourages wider market
adoption.
Competitor Insights
Key companies in anti-obesity drug market
report include:
– Eli Lilly and Company
– GlaxoSmithKline
– Novo Nordisk
– Pfizer
– AstraZeneca
– Merck & Co.
– Sanofi
– Orexigen Therapeutics
– Amgen
– Johnson & Johnson
– Abbott Laboratories
– Takeda Pharmaceutical
Company
– Zafgen
– Currax Pharmaceuticals
– Rhythm Pharmaceuticals
Key Developments
·
In
September 2025, Eli Lilly announced plans to launch its experimental weight-loss pill,
orforglipron, in India. The drug belongs to a new class of GLP-1 medicines that
help reduce appetite.
·
In
September 2025, Pfizer announced plans to acquire Metsera and its next-generation obesity
portfolio. This acquisition will help the company tackle the rising burden of
obesity by offering effective anti-obesity treatments.
·
In
March 2025, Eli Lilly announced plans to launch its blockbuster diabetes and
weight-loss drug, Mounjaro (tirzepatide), in lucrative markets like Brazil,
India, and Mexico in the second half of 2025.
Request For Customization: https://www.coherentmarketinsights.com/insight/request-customization/2824
Market
Segmentation
Drug
Type Insights (Revenue, USD Bn, 2020 – 2032)
Prescription
Drugs
Over-the-Counter
(OTC) Drugs
Drug
Class Insights (Revenue, USD Bn, 2020 – 2032)
GLP-1
Receptor Agonists
Semaglutide
Liraglutide
Tirzepatide
MC4R
(Melanocortin-4 Receptor) Agonists
Lipase
Inhibitors
Noradrenergic
& Serotonergic Drugs
Phentermine
Diethylpropion
Phendimetrazine
Combination
Therapies
Phentermine/Topiramate
Naltrexone/Bupropion
Others
Sodium-Glucose
Co-Transporter-2 (SGLT-2) Inhibitors
Empagliflozin
Canagliflozin
Bile Acid
Sequestrants
Amylin
Analogs
Others
(Late Phase Drugs, etc.)
Route
of Administration Insights (Revenue, USD Bn, 2020 – 2032)
Oral
Parenteral
Others
(Transdermal)
Type
Insights (Revenue, USD Bn, 2020 – 2032)
Gender
Insights (Revenue, USD Bn, 2020 – 2032)
Age
Group Insights (Revenue, USD Bn, 2020 – 2032)
Adult
Geriatric
Pediatric
Distribution
Channel Insights (Revenue, USD Bn, 2020 – 2032)
Retail
Pharmacies
Online
Pharmacies
Hospital
Pharmacies
Regional
Insights (Revenue, USD Bn, 2020 – 2032)
North America
Latin
America
Brazil
Argentina
Mexico
Rest of
Latin America
Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of
Europe
Asia
Pacific
China
India
Japan
Australia
South
Korea
ASEAN
Rest of
Asia Pacific
Middle
East
GCC
Countries
Israel
Rest of
Middle East
Africa
South
Africa
North
Africa
Central
Africa
Also Read: Weight Management Market
Size, Share, Trends & Opportunities for 2025-2032
Our Trusted Partners:
Worldwide Market Reports, Coherent MI, Stratagem Market Insights
Get Recent News:
https://www.coherentmarketinsights.com/news
About Us:
Coherent Market Insights leads into data and analytics,
audience measurement, consumer behaviors, and market trend analysis. From
shorter dispatch to in-depth insights, CMI has exceled in offering research,
analytics, and consumer-focused shifts for nearly a decade. With cutting-edge
syndicated tools and custom-made research services, we empower businesses to
move in the direction of growth. We are multifunctional in our work scope and
have 450+ seasoned consultants, analysts, and researchers across 26+ industries
spread out in 32+ countries.
Contact
Us:
Mr. Shah
Coherent
Market Insights Pvt. Ltd,
U.S.: +
12524771362
U.K.: +442039578553
AUS:
+61-8-7924-7805
INDIA:
+91-848-285-0837
✉ Email: sales@coherentmarketinsights.com